Respiratory Syncytial Virus Infections
Conditions
Keywords
Respiratory Syncytial Virus Infections, Placebo, Antiviral activity, JNJ-53718678
Brief summary
The purpose of this study is to evaluate the antiviral effect of repeated oral dosing of JNJ 53718678 compared to placebo in healthy adult participants infected through inoculation with respiratory syncytial virus (RSV)-A Memphis 37b virus.
Detailed description
This is a randomized (study medication assigned to participants by chance), double-blind (neither physician nor participant knows the identity of the assigned treatment), placebo-controlled, single-center study of JNJ 53718678 in healthy adult participants. Study consists of 3 phases: Screening (Day -56 and Study Day -3 prior to the planned date of virus inoculation/challenge on Study Day 0), quarantine (includes challenge on Day -1 or -2 and treatment for 7 days), and follow-up (Day 15 and 28). Participants will be admitted to the quarantine unit on Study Day -1 or - 2 and will be inoculated (intranasal) with the RSV-A Memphis 37b virus on Study Day 0. Participants will be evaluated in 3 cohorts: Cohort 1 and Cohort 3 (participants will be dosed with JNJ-53718678 or placebo for 7 days) and Cohort 2 (for up to 7 days \[Dosing Days 1-x\] \[x will be determined based on the results from Cohort 1\]). Participants will be randomized and JNJ-53718678/placebo dosing will be started after RSV presence in nasal wash has been detected by polymerase chain reaction (PCR). After completion of Cohort 1, data will be reviewed (unblinded) and the antiviral activity, safety, pharmacokinetic, clinical symptom and mucus weight data will be evaluated, based on which Cohort 2 will be initiated. Participants' safety will be monitored throughout the study.
Interventions
DRUGPlacebo
Participants will receive placebo once daily.
DRUGJNJ-53718678
Participants will receive JNJ-53718678 as 20 milliliter (mL) (200 mg) or 50 mL (500 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 1. JNJ-53718678 dose in Cohort 2 will be decided based on Cohort 1 results. JNJ-53718678 as 7.5 mL (75 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 3.
Sponsors
Janssen Sciences Ireland UC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Female participants must be of non-childbearing potential: postmenopausal for at least 2 years or surgically sterile or otherwise incapable of becoming pregnant * Female participants, except for postmenopausal women, must have a negative serum pregnancy test at screening * Participants must agree to comply with contraceptive measures as mentioned in protocol * Participants must be sero-suitable for respiratory syncytial virus (RSV) within 57 days prior to inoculation * Participants must be non-smokers for at least one month prior to screening and participants must have a negative cotinine test at screening
Exclusion criteria
* Participants with a past history of heart arrhythmias (extrasystoli, tachycardia at rest) or of risk factors for Torsade de Pointes syndrome * Participants with a history or evidence of abuse of alcohol, barbiturates, amphetamines, recreational or narcotic drug use within the past 3 months, which in the Investigator's opinion would compromise participant's safety and/or compliance with the study procedures * Participants with current human immunodeficiency virus type 1 (HIV-1) or HIV-2 infection at screening * Participants with current hepatitis A infection, or hepatitis B virus (HBV) infection, or hepatitis C virus (HCV) infection (confirmed by HCV antibody) at screening * Participants with active acute respiratory infection at admission (Study Day -1 or -2)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Area Under the Viral Load-time Curve (VL AUC) | up to Follow-up (Day 28) | VL AUC for RSV-A Memphis 37b will be determined by quantitative reverse transcriptase -polymerase chain reaction (qRT-PCR) assay of nasal wash. The VL AUC will be calculated based on the viral load values measured 2 times per day, starting with the last value prior to first dosing, and ending with the last available value before discharge. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Area Under the Viral Load-time Curve (VL AUC) Determined by Plaque Forming Unit (PFU) Assay | Baseline up to Follow-up (Day 28) | VL AUC for RSV-A Memphis 37b will be determined by PFU assay of nasal wash. |
| Viral Load Over Time | Baseline up to Follow-up (Day 28) | — |
| Peak Viral Load | Baseline up to Follow-up (Day 28) | — |
| Time To Peak Viral Load | Baseline up to Follow-up (Day 28) | Time to peak viral load will be reported. |
| Area Under the Viral Load-time Curve (VL AUC) From Time 0 to 48 Hours after First Dose | 48 hours after first dose | — |
| Time to Non-detectability of Virus | Baseline up to Follow-up (Day 28) | Time to non-detectability of virus from first administration of study drug will be assessed. |
| Total Clinical Symptom Score | Admission (Day -1 or -2) up to Day 13 | Total clinical symptom score will be assessed using a composite of 10 self-reported symptoms on the Symptom Diary Card. The Investigator will review the participant's SDC entries on a daily basis after the administration of challenge virus inoculum. Total Clinical Symptom Score ranges from 0 (no symptoms) to 3 (not well). |
| Area Under the Viral Load-time Curve (VL AUC) From Time 0 to 24 Hours after First Dose | 24 hours after first dose | — |
| Mucus Weight | Baseline up to Day 13 | — |
| Tissue Count | Baseline up to Day 13 | — |
| Sequence Analysis of the Rsv-A Memphis 37b Genome | Baseline and post-Baseline | — |
| Forced Expiratory Volume in 1 Second (FEV1) Measured by Spirometry | Baseline up to Follow-up (Day 28) | FEV1 is the amount of air that can be exhaled in one second. FEV1 will be measured by spirometry. A positive change from baseline in FEV1 indicates improvement in lung function. |
| Forced Vital Capacity (FVC) Measured by Spirometry | Baseline up to Follow-up (Day 28) | FVC is the total volume of air expired after a full inspiration. |
| FEV1/FVC Ratio | Baseline up to Follow-up (Day 28) | — |
| Time to Peak Symptom Score After Viral Inoculation | Admission (Day -1 or -2) up to Day 13 | — |
Countries
United Kingdom
Outcome results
None listed